{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:46:33Z","timestamp":1792345593574,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Many children with <jats:italic>mycoplasma pneumoniae<\/jats:italic> (MP) pneumonia (MPP) developed sequelae such as bronchiolitis\/bronchitis obliterans (BO). Early corticosteroid therapy might prevent disease progression. This study aimed to use \u201cearly\u201d corticosteroid and observe the treatment outcome in patients with MPP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who had pulmonary infiltrations on chest imaging within 5 days of the disease course and were suspected of having MP infection on admission were enrolled. Among them, patients whose disease course was within 10 days on admission were ultimately enrolled. We analyzed their data including the clinical features, the starting time and dose of corticosteroid therapy, and the treatment outcome. According to chest imaging, we divided patients into two groups (Group A: bronchiolitis-associated lesions or ground-glass opacities; Group B: pulmonary segmental\/lobar consolidation).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 210 patients with confirmed MPP were ultimately enrolled. There were 59 patients in Group A and 151 patients in Group B. Patients in Group A were more prone to have allergy histories, hypoxemia, wheezing sound, and wet rales on auscultation than those in Group B. Corticosteroid treatment was initiated between 5 and 10 days of disease onset in all patients and 6\u20137 days in most patients. Methylprednisolone was prescribed in all patients within 10 days of disease onset, and the highest prescribed dose was at least 2 mg\/kg\/day. In Group A, methylprednisolone &amp;gt;2 mg\/kg\/day was prescribed in 22 patients, and among them, 8 patients with diffuse bronchiolitis-associated lesions received high-dose methylprednisolone therapy. After 3 months, lung CT revealed slightly segmental ground-glass opacity in three patients. In Group B, methylprednisolone &amp;gt;2 mg\/kg\/day was prescribed in 76 patients, and among them, 20 patients with pulmonary lobar consolidation received high-dose methylprednisolone therapy. After 3 months, chest imaging revealed incomplete absorption of pulmonary lesions in seven patients. Among them, five patients with consolidation in more than one pulmonary lobe ultimately had slight BO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In hospitalized patients with MPP, particularly severe MPP, the ideal starting time of corticosteroid treatment might be 5\u201310 days, preferably 6\u20137 days, after disease onset. The initial dosage of corticosteroid therapy should be decided according to the severity of the disease. MPP patients with diffuse bronchiolitis-associated lesions\/whole lobar consolidation on imaging might require high-dose corticosteroid therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1135228","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:34:29Z","timestamp":1680586469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical features and \u201cearly\u201d corticosteroid treatment outcome of pediatric mycoplasma pneumoniae pneumonia"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinrong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3760\/cma.j.issn.0578-1310.2014.03.003","article-title":"[Clinical features and treatment of refractory mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children]","volume":"52","author":"Chen","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1165\/Rcmb.2004-0197oc","article-title":"mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice","volume":"32","author":"Fonseca-Aten","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/J.Jgar.2022.01.002","article-title":"Molecular features and antimicrobial susceptibility of mycoplasma pneumoniae isolates from paediatric inpatients in weihai, China: Characteristics of m. pneumoniae in weihai","volume":"28","author":"Guo","year":"2022","journal-title":"J. Glob Antimicrob. Resist."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/J.Pupt.2015.12.002","article-title":"Long-term azithromycin ameliorates not only airway inflammation but also remodeling in a murine model of chronic asthma","volume":"36","author":"Kang","year":"2016","journal-title":"Pulm Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ppul.20374","article-title":"Role of prednisolone treatment in severe mycoplasma pneumoniae pneumonia in children","volume":"41","author":"Lee","year":"2006","journal-title":"Pediatr. Pulmonol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<375::AID-PPUL10>3.0.CO;2-2","article-title":"Bronchitis obliterans due to mycoplasma pneumonia","volume":"23","author":"Leong","year":"1997","journal-title":"Pediatr. Pulmonol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/J.Jgar.2020.12.019","article-title":"First report of macrolide-resistant and -susceptible mycoplasma pneumoniae clinical strains isolated from a single case","volume":"24","author":"Li","year":"2021","journal-title":"J. Glob Antimicrob. Resist."},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/S12879-020-4774-9","article-title":"mycoplasma pneumoniae pneumonia associated thrombosis At Beijing children's hospital","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00296","article-title":"Low bacterial Co-infection invalidates the early use of non-Anti-mycoplasma pneumoniae antibiotics in pediatric refractory mycoplasma pneumoniae pneumonia patients","volume":"6","author":"Liu","year":"2018","journal-title":"Front. Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3760\/cma.j.issn.0578-1310.2012.12.010","article-title":"[Clinical characteristics and predictive factors of refractory mycoplasma pneumoniae pneumonia]","volume":"50","author":"Liu","year":"2012","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s11684-021-0840-Y","article-title":"Proteomics study of mycoplasma pneumoniae pneumonia reveals the fc fragment of the igg-binding protein as a serum biomarker and implicates potential therapeutic targets","volume":"16","author":"Liu","year":"2022","journal-title":"Front. Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/S12879-019-4667-Y","article-title":"High mycoplasma pneumoniae loads and persistent long-term mycoplasma pneumoniae dna in lower airway associated with severity of pediatric mycoplasma pneumoniae pneumonia","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/Infdis\/Jix559","article-title":"The role of b cells in carriage and clearance of mycoplasma pneumoniae from the respiratory tract of mice","volume":"217","author":"Meyer Sauteur","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/Cmi.12810","article-title":"Modelling persistent mycoplasma pneumoniae infection of human airway epithelium","volume":"20","author":"Prince","year":"2018","journal-title":"Cell Microbiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/Iai.00878-07","article-title":"Intranasal interleukin-12 therapy inhibits mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia","volume":"76","author":"Salvatore","year":"2008","journal-title":"Infect. Immun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/Ppul.22650","article-title":"Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant mycoplasma pneumoniae infection: A case report","volume":"48","author":"Shen","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/J.1365-2567.2011.03408.X","article-title":"Cytoadherence-dependent induction of inflammatory responses by mycoplasma pneumoniae","volume":"133","author":"Shimizu","year":"2011","journal-title":"Immunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.issn.0578-1310.2013.10.006","article-title":"[Guidelines for management of community acquired pneumonia in children (The revised edition of 2013) (I)]","volume":"51","year":"2013","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jinf.2008.06.012","article-title":"Methylprednisolone pulse therapy for refractory mycoplasma pneumoniae pneumonia in children","volume":"57","author":"Tamura","year":"2008","journal-title":"J. Infect."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/Jcm11102824","article-title":"Refractory mycoplasma pneumoniae pneumonia in children: Early recognition and management","volume":"11","author":"Tong","year":"2022","journal-title":"J. Clin. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.17219\/Acem\/76170","article-title":"Roles of the mammalian target of rapamycin (Mtor) signaling pathway in the repair of hyperoxia-induced acute lung injury","volume":"29","author":"Wang","year":"2020","journal-title":"Adv. Clin. Exp. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ped4.12108","article-title":"Clinicoradiologic features of mycoplasma pneumoniae bronchiolitis in children","volume":"2","author":"Wen","year":"2018","journal-title":"Pediatr. Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"39929","DOI":"10.1038\/srep39929","article-title":"The clinical characteristics of corticosteroid-resistant refractory mycoplasma pneumoniae pneumonia in children","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050726","article-title":"Early corticosteroid therapy for mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children","volume":"8","author":"Yang","year":"2019","journal-title":"J. Clin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4168\/aair.2014.6.1.22","article-title":"Effects of methylprednisolone pulse therapy on refractory mycoplasma pneumoniae pneumonia in children","volume":"6","author":"You","year":"2014","journal-title":"Allergy Asthma Immunol. Res."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/Fped.2021.741663","article-title":"Case report: Clinical analysis of fulminant mycoplasma pneumoniae pneumonia in children","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13756-019-0469-7","article-title":"Antimicrobial susceptibility and genotyping of mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016","volume":"8","author":"Zhao","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/Journal.Pone.0141702","article-title":"Culture-independent detection and genotyping of mycoplasma pneumoniae in clinical specimens from Beijing, China","volume":"10","author":"Zhao","year":"2015","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/Fcimb.2020.553739","article-title":"Pathogenic analysis of the bronchoalveolar lavage fluid samples with pediatric refractory mycoplasma pneumoniae pneumonia","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8478","DOI":"10.1038\/S41598-017-08861-7","article-title":"mycoplasma pneumoniae-associated bronchiolitis obliterans following acute bronchiolitis","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1135228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:34:36Z","timestamp":1680586476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1135228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":30,"alternative-id":["10.3389\/fcimb.2023.1135228"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1135228","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1135228"}}